CoChat
Sign Up
Cited by 167Antifungal resistance and susceptibilityFungal and yeast genetics researchBacterial biofilms and quorum sensing

Biofilm formation in medically important Candida species

Open access
Malinovská, Zuzana, Čonková, Eva, Váczi, Peter·2023·Journal of Fungi
DOI 10.3390/jof9100955PMC PMC10607155
Open this paper in CoChat — free accountOpen PDF

Abstract

Worldwide, the number of infections caused by biofilm-forming fungal pathogens is very high. In human medicine, there is an increasing proportion of immunocompromised patients with prolonged hospitalization, and patients with long-term inserted drains, cannulas, catheters, tubes, or other artificial devices, that exhibit a predisposition for colonization by biofilm-forming yeasts. A high percentage of mortality is due to candidemia caused by medically important Candida species. Species of major clinical significance include C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, C. krusei, and C. auris. The association of these pathogenic species in the biofilm structure is a serious therapeutic problem. Candida cells growing in the form of a biofilm are able to resist persistent therapy thanks to a combination of their protective mechanisms and their ability to disseminate to other parts of the body, thus representing a threat from the perspective of a permanent source of infection. The elucidation of the key mechanisms of biofilm formation is essential to progress in the understanding and treatment of invasive Candida infections.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jof9100955

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Biofilm formation is a complex process; adhesion to living or inert surfaces represents the first stage, and other steps are required including morphogenetic changes, proliferation, and maturation.

    “Biofilm formation is a complex process. While adhesion to living or inert surfaces represents the first stage, other steps are required including morphogenetic changes, proliferation, and maturation (14).”

    From Ume6-dependent pathways of morphogenesis and biofilm formation in <i>Candida auris</i> (2024) · cites this paper as [14]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 106

  1. [1]Fanning S. Mitchell A.P. Fungal biofilms PLoS Pathog. 2012 8 e1002585 10.1371/journal.ppat.1002585 22496639 PMC3320593 · DOI · Paper page
  2. [2]Lohse M.B. Gulati M. Johnson A.D. Nobile C.J. Development and regulation of single-and multi-species Candida albicans biofilms Nat. Rev. Microbiol. 2018 16 19 31 10.1038/nrmicro.2017.107 29062072 PMC5726514 · DOI · Paper page
  3. [3]Pohl C.H. Recent advances and opportunities in the study of Candida albicans polymicrobial biofilms Front. Cell. Infect. Microbiol. 2022 12 836379 10.3389/fcimb.2022.836379 35252039 PMC8894716 · DOI
  4. [4]Ponde N.O. Lortal L. Ramage G. Naglik J.R. Richardson J.P. Candida albicans biofilms and polymicrobial interactions Crit. Rev. Microbiol. 2021 47 91 111 10.1080/1040841X.2020.1843400 33482069 PMC7903066 · DOI · Paper page
  5. [5]Vitális E. Nagy F. Tóth Z. Forgács L. Bozó A. Kardos G. Majoros L. Kovács R. Candida biofilm production is associated with higher mortality in patients with candidaemia Mycoses 2020 63 352 360 10.1111/myc.13049 31943428 · DOI
  6. [6]Cannizzo F.T. Eraso E. Ezkurra P.A. Villar-Vidal M. Bollo E. Castellá G. Cabañes F.J. Vidotto V. Quindós G. Biofilm development by clinical isolates of Malassezia pachydermatis Med. Mycol. 2007 45 357 361 10.1080/13693780701225767 17510859 · DOI
  7. [7]Nami S. Aghebati-Maleki A. Morovati H. Aghebati-Maleki L. Current antifungal drugs and immunotherapeutic approaches as promising strategies to treatment of fungal diseases Biomed. Pharmacother. 2019 110 857 868 10.1016/j.biopha.2018.12.009 30557835 · DOI
  8. [8]Marak M.B. Dhanashree B. Antifungal susceptibility and biofilm production of Candida spp. isolated from clinical samples Int. J. Microbiol. 2018 2018 7495218 10.1155/2018/7495218 30405717 PMC6199855 · DOI
  9. [9]Maccallum D.M. Hosting infection: Experimental models to assay Candida virulence Int. J. Microbiol. 2012 2012 363764 10.1155/2012/363764 22235206 PMC3253448 · DOI
  10. [10]Ciurea C.N. Kosovski I.B. Mare A.D. Toma F. Pintea-Simon I.A. Man A. Candida and candidiasis-opportunism versus pathogenicity: A review of the virulence traits Microorganisms 2020 8 857 10.3390/microorganisms8060857 32517179 PMC7355540 · DOI
  11. [11]Borman A.M. Johnson E.M. Name changes for fungi of medical importance, 2018 to 2019 J. Clin. Microbiol. 2021 59 e01811-20 10.1128/JCM.01811-20 33028600 PMC8111128 · DOI
  12. [12]McCarty T.P. White C.M. Pappas P.G. Candidemia and invasive candidiasis Infect. Dis. Clin. N. Am. 2021 35 389 413 10.1016/j.idc.2021.03.007 34016283 · DOI · Paper page
  13. [13]Eggimann P. Pittet D. Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later Intensive Care Med. 2014 40 1429 1448 10.1007/s00134-014-3355-z 24934813 PMC4176828 · DOI
  14. [14]Satoh K. Makimura K. Hasumi Y. Nishiyama Y. Uchida K. Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital Microbiol. Immunol. 2009 53 41 44 10.1111/j.1348-0421.2008.00083.x 19161556 · DOI · Paper page
  15. [15]Manzano-Gayosso P. Hernandez-Hernandez F. Zavala-Velasquez N. Mendez-Tovar L.J. Naquid-Narvaez J.M. Torres-Rodriguez J.M. Lopez-Martinez R. Candiduria in type 2 diabetes mellitus patients and its clinical significance. Candida spp. antifungal susceptibility Rev. Med. Inst. Mex. Seguro Soc. 2008 46 603 610 19263663
  16. [16]Sikora A. Hashmi M.F. Zahra F. Candida Auris StatPearls StatPearls Publishing Treasure Island, FL, USA 2023 33085444
  17. [17]Lee W.G. Shin J.H. Uh Y. Kang M.G. Kim S.H. Park K.H. Jang H.C. First three reported cases of nosocomial fungemia caused by Candida auris J. Clin. Microbiol. 2011 49 3139 3142 10.1128/JCM.00319-11 21715586 PMC3165631 · DOI
  18. [18]Lockhart S.R. Etienne K.A. Vallabhaneni S. Farooqi J. Chowdhary A. Govender N.P. Lopes Colombo A. Calvo B. Cuomo C.A. Desjardins C.A. Simultaneous emergence of multidrug resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses Clin. Infect. Dis. 2017 64 134 140 10.1093/cid/ciw691 27988485 PMC5215215 · DOI · Paper page
  19. [19]Sahal G. Bilkay I.S. Distribution of clinical isolates of Candida spp. and antifungal susceptibility of high biofilm-forming Candida isolates Rev. Soc. Bras. Med. Trop. 2018 51 644 650 10.1590/0037-8682-0136-2018 30304271 · DOI
  20. [20]Mohandas V. Ballal M. Distribution of Candida species in different clinical samples and their virulence: Biofilm formation, proteinase and phospholipase production: A study on hospitalized patients in Southern India J. Glob. Infect. Dis. 2011 2 4 8 10.4103/0974-777X.77288 PMC3068577 21572601 · DOI
  21. [21]Lagunes L. Rello J. Invasive candidiasis: From mycobiome to infection, therapy, and prevention Eur. J. Clin. Microbiol. Infect. Dis. 2016 35 1221 1226 10.1007/s10096-016-2658-0 27146877 · DOI
  22. [24]Forsberg K. Woodworth K. Walters M. Berkow L. Jackson B. Chiller T. Vallabhaneni S. Candida auris: The recent emergence of a multidrug-resistant fungal pathogen Med. Mycol. 2019 57 1 12 10.1093/mmy/myy054 30085270 · DOI · Paper page
  23. [25]Spivak E.S. Hanson K.E. Candida auris: An emerging fungal pathogen J. Clin. Microbiol. 2018 56 e01588-17 10.1128/JCM.01588-17 29167291 PMC5786713 · DOI · Paper page
  24. [26]Biswal M. Rudramurthy S.M. Jain N. Shamanth A.S. Sharma D. Jain K. Yaddanapudi L.N. Chakrabarti A. Controlling a possible outbreak of Candida auris infection: Lessons learnt from multiple interventions J. Hosp. Infect. 2017 97 363 370 10.1016/j.jhin.2017.09.009 28939316 · DOI
  25. [27]Piedrahita C.T. Cadnum J.L. Jencson A.L. Shaikh A.A. Ghannoum M.A. Donskey C.J. Environmental surfaces in healthcare facilities are a potential source for transmission of Candida auris and other Candida species Infect. Control Hosp Epidemiol. 2017 38 1107 1109 10.1017/ice.2017.127 28693657 · DOI
  26. [28]Welsh R.M. Bentz M.L. Shams A. Houston H. Lyons A. Rose L.J. Litvintseva A.P. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface J. Clin. Microbiol. 2017 55 2996 3005 10.1128/JCM.00921-17 28747370 PMC5625385 · DOI · Paper page
  27. [29]Dire O. Ahmad A. Duze S. Patel M. Survival of Candida auris on environmental surface materials and low-level resistance to disinfectant J. Hosp. Infect. 2023 137 17 23 10.1016/j.jhin.2023.04.007 37116661 · DOI · Paper page
  28. [30]Diekema D. Arbefeville S. Boyken L. Kroeger J. Pfaller M. The changing epidemiology of healthcare-associated candidemia over three decades Diagn. Microbiol. Infect. Dis. 2012 73 45 48 10.1016/j.diagmicrobio.2012.02.001 22578938 · DOI · Paper page
  29. [31]Pfaller M.A. Diekema D.J. Turnidge J.D. Castanheira M. Jones R.N. Twenty Years of the SENTRY antifungal surveillance program: Results for Candida species from 1997–2016 Open Forum Infect. Dis. 2019 6 79 94 10.1093/ofid/ofy358 PMC6419901 30895218 · DOI · Paper page
  30. [32]Chakrabarti A. Sood P. Rudramurthy S.M. Chen S. Kaur H. Capoor M. Chhina D. Rao R. Eshwara V.K. Xess I. Incidence, characteristics and outcome of ICU-acquired candidemia in India Intensive Care Med. 2015 41 285 295 10.1007/s00134-014-3603-2 25510301 · DOI · Paper page
  31. [34]Atiencia-Carrera M.B. Cabezas-Mera F.S. Tejera E. Machado A. Prevalence of biofilms in Candida spp. bloodstream infections: A meta-analysis PLoS ONE 2022 17 e0263522 10.1371/journal.pone.0263522 35113972 PMC8812928 · DOI
  32. [35]Horn D.L. Neofytos D. Anaissie E.J. Fishman J.A. Steinbach W.J. Olyaei A.J. Marr K.A. Pfaller M.A. Chang C.H. Webster K.M. Epidemiology and outcomes of candidemia in 2019 patients: Data from the prospective antifungal therapy alliance registry Clin. Infect. Dis. 2009 48 1695 1703 10.1086/599039 19441981 · DOI · Paper page
  33. [37]Gómez-Gaviria M. Mora-Montes H.M. Current aspects in the biology, pathogeny, and treatment of Candida krusei, a neglected fungal pathogen Infect. Drug Resist. 2020 13 1673 1689 10.2147/IDR.S247944 32606818 PMC7293913 · DOI
  34. [38]Navarro-Arias M.J. Hernández-Chávez M.J. García-Carnero L.C. Amezcua-Hernández D.G. Lozoya-Pérez N.E. Estrada-Mata E. Martínez-Duncker I. Franco B. Mora-Montes H.M. Differential recognition of Candida tropicalis, Candida guilliermondii, Candida krusei, and Candida auris by human innate immune cells Infect. Drug Resist. 2019 12 783 794 10.2147/IDR.S197531 31040708 PMC6459152 · DOI
  35. [39]Johnson C.J. Davis J.M. Huttenlocher A. Kernien J.F. Nett J.E. Emerging fungal pathogen Candida auris evades neutrophil attack MBio 2018 9 e01403-18 10.1128/mBio.01403-18 30131360 PMC6106086 · DOI · Paper page
  36. [40]Chandra J. Mukherjee P. Candida biofilms: Development, architecture, and resistance Microbiol. Spectr. 2015 3 115 134 10.1128/microbiolspec.MB-0020-2015 PMC4566167 26350306 · DOI
  37. [41]Seneviratne C.J. Jin L. Samaranayake L.P. Biofilm lifestyle of Candida: A mini review Oral Dis. 2008 14 582 590 10.1111/j.1601-0825.2007.01424.x 19076549 · DOI · Paper page
  38. [42]Las Penčz de A. Pan S.J. CastaĖo I. Alder J. Cregg R. Cormack B.P. Virulence-related surface glycoproteins in the yeast pathogen Candida glabrata are encoded in subtelomeric clusters and subject to RAP-1 and SIRdependent transcriptional silencing Genes Dev. 2003 17 2245 2258 10.1101/gad.1121003 12952896 PMC196462 · DOI · Paper page
  39. [43]Wang D. An N. Yang Y. Yang X. Fan Y. Feng J. Candida tropicalis distribution and drug resistance is correlated with ERG11 and UPC2 expression Antimicrob. Resist. Infect. Control 2021 10 54 10.1186/s13756-021-00890-2 33722286 PMC7958445 · DOI · Paper page
  40. [45]Yamin D.H. Husin A. Harun A. Risk factors of Candida parapsilosis catheter-related bloodstream infection Front. Public Health 2021 9 631865 10.3389/fpubh.2021.631865 34458217 PMC8387826 · DOI
  41. [46]Harrington R. Kindermann S.L. Hou Q. Taylor R.J. Azie N. Horn D.L. Candidemia and invasive candidiasis among hospitalized neonates and pediatric patients Curr. Med. Res. Opin. 2017 33 1803 1812 10.1080/03007995.2017.1354824 28699797 · DOI
  42. [47]Dranginis A.M. Rauceo J.M. Coronado J.E. Lipke P.N. A biochemical guide to yeast adhesins: Glycoproteins for social and antisocial occasions Microb. Mol. Biol. Rev. 2007 71 282 294 10.1128/MMBR.00037-06 17554046 PMC1899881 · DOI
  43. [48]Weig M. Jänsch L. Gross U. De Koster C.G. Klis F.M. De Groot P.W. Systematic identification in silico of covalently bound cell wall proteins and analysis of proteinpolysaccharide linkages of the human pathoge Candida glabrata Microbiology 2004 150 3129 3144 10.1099/mic.0.27256-0 15470094 · DOI
  44. [49]Bing J. Guan Z. Zheng T. Zhang Z. Fan S. Ennis C.L. Nobile C.J. Huang G. Clinical isolates of Candida auris with enhanced adherence and biofilm formation due to genomic amplification of ALS4 PLoS Pathog. 2023 19 e1011239 10.1371/journal.ppat.1011239 36913408 PMC10035925 · DOI · Paper page
  45. [51]Hoyer L.L. The ALS gene family of Candida albicans Trends Microbiol. 2001 9 176 180 10.1016/S0966-842X(01)01984-9 11286882 · DOI · Paper page
  46. [52]Modrezewka B. Kurnatowski P. Adherence of Candida sp. to host tissues and cells as one of its pathogenicity features Ann. Parasitol. 2015 61 3 9 25911031
  47. [53]Panagoda G.J. Ellepola A.N. Samaranayake L.P. Adhesion of Candida parapsilosis to epithelial and acrylic surfaces correlates with cell surface hydrophobicity Mycoses 2001 44 29 35 10.1046/j.1439-0507.2001.00611.x 11398638 · DOI
  48. [54]Berila N. Subík J. Oportúnne patogénna kvasinka Candida glabrata a jej mechanizmy rezistencie voci antimykotikám (súborný referát) [Opportunistic pathogen Candida glabrata and the mechanisms of its resistance to antifungal drugs] Epidemiol. Mikrobiol. Imunol. 2010 59 67 79 20586168
  49. [56]Borman A.M. Szekely A. Johnson E.M. Comparative pathogenicity of United Kingdom isolates of the emerging pathogen Candida auris and other key pathogenic Candida species MSphere 2016 1 e00189-16 10.1128/mSphere.00189-16 27547827 PMC4990711 · DOI · Paper page
  50. [57]Fakhim H. Vaezi A. Dannaoui E. Chowdhary A. Nasiry D. Faeli L. Meis J.F. Badali H. Comparative virulence of Candida auris with Candida haemulonii, Candida glabrata and Candida albicans in a murine model Mycoses 2018 61 377 382 10.1111/myc.12754 29460345 · DOI
  51. [58]Brown J.L. Delaney C. Short B. Butcher M.C. McKloud E. Williams C. Kean R. Ramage G. Candida auris phenotypic heterogeneity determines pathogenicity in vitro MSphere 2020 5 e00371-20 10.1128/mSphere.00371-20 32581078 PMC7316489 · DOI · Paper page
  52. [60]Jabeen K. Mal P.B. Tharwani A. Hashmi M. Farooqi J. Persistence of Candida auris on latex and nitrile gloves with transmission to sterile urinary catheters Med. Mycol. 2020 58 128 132 10.1093/mmy/myz033 31032857 · DOI
  53. [61]Al-Fattani M.A. Douglas L.J. Biofilm matrix of Candida albicans and Candida tropicalis: Chemical composition and role in drug resistance J. Med. Microbiol. 2006 55 999 1008 10.1099/jmm.0.46569-0 16849719 · DOI · Paper page
  54. [62]Blankenship J.R. Mitchell A.P. How to build a biofilm: A fungal perspective Curr. Opin. Microbiol. 2006 9 588 594 10.1016/j.mib.2006.10.003 17055772 · DOI · Paper page
  55. [63]Řičicová M. Kucharíková S. Tournu H. Hendrix J. Bujdáková H. Van Eldere J. Lagrou K. Van Dijck P. Candida albicans biofilm formation in a new in vivo rat model Microbiology 2010 156 909 919 10.1099/mic.0.033530-0 19959578 · DOI
  56. [65]Kucharikova S. Neirinck B. Sharma N. Vleugels J. Lagrou K. Van Dijck P. In vivo Candida glabrata biofilm development on foreign bodies in a rat subcutaneous model J. Antimicrob. Chemother. 2014 70 846 856 10.1093/jac/dku447 25406296 · DOI
  57. [66]Tseng Y.K. Chen Y.C. Hou C.J. Deng F.S. Liang S.H. Hoo S.Y. Hsu C.C. Ke C.L. Lin C.H. Evaluation of biofilm formation in Candida tropicalis using a silicone-based platform with synthetic urine medium Microorganisms 2020 8 660 10.3390/microorganisms8050660 32369936 PMC7284471 · DOI
  58. [67]Harrison J. Ceri H. Yerly J. Rabiei M. Hu Y. Martinuzzi R. Turner R.J. Metal ions may suppress or enhance cellular differentiation in Candida albicans and Candida tropicalis biofilms Appl. Environ. Microbiol. 2007 73 4940 4949 10.1128/AEM.02711-06 17557844 PMC1951024 · DOI
  59. [68]Mitchell K.F. Zarnowski R. Andes D.R. The extracellular matrix of fungal biofilms Adv. Exp. Med. Biol. 2016 931 21 35 27271680
  60. [70]Mitchell K.F. Zarnowski R. Sanchez H. Edward J.A. Reinicke E.L. Nett J.E. Mitchell A.P. Andes D.R. Community participation in biofilm matrix assembly and function Proc. Natl. Acad. Sci. USA 2015 112 4092 4097 10.1073/pnas.1421437112 25770218 PMC4386410 · DOI · Paper page
  61. [71]Pathak A.K. Sharma S. Shrivastva P. Multi-species biofilm of Candida albicans and non-Candida albicans Candida species on acrylic substrate J. Appl. Oral Sci. 2012 20 70 75 10.1590/S1678-77572012000100013 22437681 PMC3928775 · DOI
  62. [73]Trofa D. Gácser A. Nosanchuk J.D. Candida parapsilosis, an emerging fungal pathogen Clin. Microbiol. Rev. 2008 21 606 625 10.1128/CMR.00013-08 18854483 PMC2570155 · DOI
  63. [74]Ding C. Butler G. Development of a gene knockout system in Candida parapsilosis reveals a conserved role for BCR1 in biofilm formation Eukaryot. Cell 2007 6 1310 1319 10.1128/EC.00136-07 17586721 PMC1951126 · DOI
  64. [75]Yigit N. Aktas E. Dagistan S. Ayyildiz A. Investigating biofilm production, coagulase and hemolytic activity in Candida species isolated from denture stomatitis patients Eurasian J. Med. 2011 43 27 32 10.5152/eajm.2011.06 25610156 PMC4261369 · DOI
  65. [76]Barros P.P. Ribeiro F.C. Rossoni R.D. Junqueira J.C. Jorge O. Influence of Candida krusei and Candida glabrata on Candida albicans gene expression in in vitro biofilms Arch. Oral Biol. 2016 64 92 101 10.1016/j.archoralbio.2016.01.005 26803674 · DOI
  66. [77]Thein Z.M. Samaranayake Y.H. Samaranayake L.P. Characteristics of dual species Candida biofilms on denture acrylic surfaces Arch Oral Biol. 2007 52 1200 1208 10.1016/j.archoralbio.2007.06.007 17681271 · DOI
  67. [79]Wang X. Bing J. Zheng Q. Zhang F. Liu J. Yue H. Tao L. Du H. Wang Y. Wang H. The first isolate of Candida auris in China: Clinical and biological aspects Emerg. Microbes Infect. 2018 7 93 10.1038/s41426-018-0095-0 29777096 PMC5959928 · DOI · Paper page
  68. [80]Chowdhary A. Sharma C. Duggal S. Agarwal K. Prakash A. Singh P.K. Jain S. Kathuria S. Randhawa H.S. Hagen F. New clonal strain of Candida auris, Delhi, India Emerg. Infect. Dis. 2013 19 1670 1673 10.3201/eid1910.130393 24048006 PMC3810747 · DOI
  69. [84]Chow N.A. de Groot T. Badali H. Abastabar M. Chiller T.M. Meis J.F. Potential fifth clade of Candida auris, Iran, 2018 Emerg. Infect. Dis. 2019 25 1780 1781 10.3201/eid2509.190686 31310230 PMC6711235 · DOI · Paper page
  70. [85]Atriwal T. Azeem K. Husain F.M. Hussain A. Khan M.N. Alajmi M.F. Abid M. Mechanistic understanding of Candida albicans biofilm formation and approaches for its inhibition Front. Microbiol. 2021 12 638609 10.3389/fmicb.2021.638609 33995297 PMC8121174 · DOI
  71. [86]Rodríguez-Cerdeira C. Gregorio M.C. Molares-Vila A. López-Barcenas A. Fabbrocini G. Bardhi B. Sinani A. Sánchez-Blanco E. Arenas-Guzmán R. Hernandez-Castro R. Biofilms and vulvovaginal candidiasis Colloids Surf. B. Biointerfaces 2019 174 110 125 10.1016/j.colsurfb.2018.11.011 30447520 · DOI
  72. [87]Finkel J.S. Mitchell A.P. Genetic control of Candida albicans biofilm development Nat. Rev. Microbiol. 2011 9 109 118 10.1038/nrmicro2475 21189476 PMC3891587 · DOI
  73. [88]Fox E.P. Bui C.K. Nett J.E. Hartooni N. Mui M.C. Andes D.R. Nobile C.J. Johnson A.D. An expanded regulatory network temporally controls Candida albicans biofilm formation Mol. Microbiol. 2015 96 1226 1239 10.1111/mmi.13002 25784162 PMC4464956 · DOI · Paper page
  74. [90]Nobile C.J. Mitchell A.P. Regulation of cell-surface genes and biofilm formation by the C. albicans transcription factor Bcr1p Curr. Biol. 2005 15 1150 1155 10.1016/j.cub.2005.05.047 15964282 · DOI · Paper page
  75. [91]de Barros P.P. Freire F. Rossoni R.D. Junqueira J.C. Jorge A.O.C. Candida krusei and Candida glabrata reduce the filamentation of Candida albicans by downregulating expression of HWP1 gene Folia Microbiol. 2017 62 317 323 10.1007/s12223-017-0500-4 28164244 · DOI
  76. [92]Karkowska-Kuleta J. Zajac D. Bochenska O. Kozik A. Surfaceome of pathogenic yeasts, Candida parapsilosis and Candida tropicalis, revealed with the use of cell surface shaving method and shotgun proteomic approach Acta Biochim. Pol. 2015 62 807 819 10.18388/abp.2015_1140 26636137 · DOI
  77. [93]Ganguly S. Bishop A.C. Xu W. Ghosh S. Nickerson K.W. Lanni F. Patton-Vogt J. Mitchell A.P. Zap1 control of cell-cell signaling in Candida albicans biofilms Eukaryot. Cell 2011 10 1448 1454 10.1128/EC.05196-11 21890817 PMC3209068 · DOI
  78. [94]Sachivkina N. Podoprigora I. Bokov D. Morphological characteristics of Candida albicans, Candida krusei, Candida guilliermondii, and Candida glabrata biofilms, and response to farnesol Vet. World 2021 14 1608 1614 10.14202/vetworld.2021.1608-1614 34316210 PMC8304438 · DOI
  79. [96]Uppuluri P. Chaturvedi A.K. Srinivasan A. Banerjee M. Ramasubramaniam A.K. Köhler J.R. Kadosh D. Lopez-Ribot J.L. Dispersion as an important step in the Candida albicans biofilm developmental cycle PLoS Pathog. 2010 6 e1000828 10.1371/journal.ppat.1000828 20360962 PMC2847914 · DOI · Paper page
  80. [98]Uppuluri P. Acosta Zaldívar M. Anderson M.Z. Dunn M.J. Berman J. Lopez Ribot J.L. Köhler J.R. Candida albicans dispersed cells are developmentally distinct from biofilm and planktonic cells MBio 2018 9 e01338-18 10.1128/mBio.01338-18 30131358 PMC6106089 · DOI
  81. [99]Winter M.B. Salcedo E.C. Lohse M.B. Hartooni N. Gulati M. Sanchez H. Takagi J. Hube B. Andes D.R. Johnson A.D. Global identification of biofilm-specific proteolysis in Candida albicans MBio 2016 7 e01514-16 10.1128/mBio.01514-16 27624133 PMC5021810 · DOI
  82. [100]Nett J. Lincoln L. Marchillo K. Massey R. Holoyda K. Hoff B. VanHandel M. Andes D. Putative role of β-1,3 glucans in Candida albicans biofilm resistance Antimicrob. Agents Chemother. 2007 51 510 520 10.1128/AAC.01056-06 17130296 PMC1797745 · DOI · Paper page
  83. [101]Bellmann R. Smuszkiewicz P. Pharmacokinetics of antifungal drugs: Practical implications for optimized treatment of patients Infection 2017 45 737 779 10.1007/s15010-017-1042-z 28702763 PMC5696449 · DOI
  84. [102]Fan X. Xiao M. Liao K. Kudinha T. Wang H. Zhang L. Hou X. Kong F. Xu Y.C. Notable increasing trend in azole non-susceptible Candida tropicalis causing invasive candidiasis in China (August 2009 to July 2014): Molecular epidemiology and clinical azole consumption Front. Microbiol. 2017 8 464 10.3389/fmicb.2017.00464 28382028 PMC5360734 · DOI · Paper page
  85. [103]Frías-De-León M.G. Hernández-Castro R. Vite-Garín T. Arenas R. Bonifaz A. Castañón-Olivares L. Acosta-Altamirano G. Martínez-Herrera E. Antifungal Resistance in Candida auris: Molecular determinants Antibiotics 2020 9 568 10.3390/antibiotics9090568 32887362 PMC7558570 · DOI · Paper page
  86. [104]Dhingra S. Cramer R.A. Regulation of sterol biosynthesis in the human fungal pathogen Aspergillus fumigatus: Opportunities for therapeutic development Front. Microbiol. 2017 8 92 10.3389/fmicb.2017.00092 28203225 PMC5285346 · DOI
  87. [105]Bhattacharya S. Esquivel B.D. White T.C. Overexpression or deletion of ergosterol biosynthesis genes alters doubling time, response to stress agents, and drug susceptibility in Saccharomyces cerevisiae MBio 2018 9 e01291-18 10.1128/mBio.01291-18 30042199 PMC6058291 · DOI · Paper page
  88. [107]Khosravi Rad K. Falahati M. Roudbary M. Farahyar S. Nami S. Overexpression of MDR-1 and CDR-2 genes in fluconazole resistance of Candida albicans isolated from patients with vulvovaginal candidiasis Curr. Med. Mycol. 2016 2 24 29 10.18869/acadpub.cmm.2.4.24 28959792 PMC5611693 · DOI
  89. [108]Ben-Ami R. Berman J. Novikov A. Bash E. Shachor-Meyouhas Y. Zakin S. Maor Y. Tarabia J. Schechner V. Adler A. Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel Emerg. Infect. Dis. 2017 23 195 203 10.3201/eid2302.161486 28098529 PMC5324804 · DOI · Paper page
  90. [110]Spampinato C. Leonardi D. Candida infections, causes, targets, and resistance mechanisms: Traditional and alternative antifungal agents Biomed. Res. Int. 2013 2013 204237 10.1155/2013/204237 23878798 PMC3708393 · DOI · Paper page
  91. [111]Trong Le N. Viet Ho D. Quoc Doan T. Tuan Le A. Raal A. Usai D. Sanna G. Carta A. Rappelli P. Diaz N. Biological activities of essential oils from leaves of Paramignya trimera (Oliv.) Guillaum and Limnocitrus littoralis (Miq.) Swingle Antibiotics 2020 9 207 10.3390/antibiotics9040207 32344551 PMC7235712 · DOI
  92. [112]Karpiński T.M. Ożarowski M. Seremak-Mrozikiewicz A. Wolski H. Anti-Candida and antibiofilm activity of selected Lamiaceae essential oils Front. Biosci. 2023 28 28 10.31083/j.fbl2802028 36866556 · DOI
  93. [113]El-Baz A.M. Mosbah R.A. Goda R.M. Mansour B. Sultana T. Dahms T.E.S. El-Ganiny A.M. Back to nature: Combating Candida albicans biofilm, phospholipase and hemolysin using plant essential oils Antibiotics 2021 10 81 10.3390/antibiotics10010081 33467766 PMC7830859 · DOI
  94. [114]Hacioglu M. Oyardi O. Kirinti A. Oregano essential oil inhibits Candida spp. biofilms Z. Naturforsch. C. J. Biosci. 2021 76 443 450 10.1515/znc-2021-0002 33915040 · DOI
  95. [115]Karpiński T.M. Ożarowski M. Seremak-Mrozikiewicz A. Wolski H. Adamczak A. Plant preparations and compounds with activities against biofilms formed by Candida spp. J. Fungi 2021 7 360 10.3390/jof7050360 PMC8147947 34063007 · DOI
  96. [116]Jafri H. Ahmad I. Thymus vulgaris essential oil and thymol inhibit biofilms and interact synergistically with antifungal drugs against drug resistant strains of Candida albicans and Candida tropicalis J. Mycol. Med. 2020 30 100911 10.1016/j.mycmed.2019.100911 32008964 · DOI
  97. [117]Singla R.K. Dubey A.K. Molecules and metabolites from natural products as inhibitors of biofilm in Candida spp. pathogens Curr. Top. Med. Chem. 2019 19 2567 2578 10.2174/1568026619666191025154834 31654510 PMC7403689 · DOI
  98. [118]Soliman S.S.M. Semreen M.H. El-Keblawy A.A. Abdullah A. Uppuluri P. Ibrahim A.S. Assessment of herbal drugs for promising anti-Candida activity BMC Complement. Altern. Med. 2017 17 257 10.1186/s12906-017-1760-x 28482836 PMC5422888 · DOI
  99. [119]Serra E. Hidalgo-Bastida L.A. Verran J. Williams D. Malic S. Antifungal activity of commercial essential oils and biocides against Candida albicans Pathogens 2018 7 15 10.3390/pathogens7010015 29370147 PMC5874741 · DOI
  100. [120]Dalleau S. Cateau E. Bergès T. Berjeaud J.M. Imbert C. In vitro activity of terpenes against Candida biofilms Int. J. Antimicrob. Agents 2008 31 572 576 10.1016/j.ijantimicag.2008.01.028 18440786 · DOI
  101. [121]Zore G.B. Thakre A.D. Jadhav S. Karuppayil S.M. Terpenoids inhibit Candida albicans growth by affecting membrane integrity and arrest of cell cycle Phytomedicine 2011 18 1181 1190 10.1016/j.phymed.2011.03.008 21596542 · DOI · Paper page
  102. [122]Dal Mas C. Rossato L. Shimizu T. Oliveira E.B. da Silva Junior P.I. Meis J.F. Lopes Colombo A. Hayashi M.A.F. Effects of the natural peptide crotamine from a South American rattlesnake on Candida auris, an emergent multidrug antifungal resistant human pathogen Biomolecules 2019 9 205 10.3390/biom9060205 31141959 PMC6627186 · DOI
  103. [123]Barreto T.L. Rossato L. de Freitas A.L.D. Meis J.F. Lopes L.B. Colombo A.L. Ishida K. Miltefosine as an alternative strategy in the treatment of the emerging fungus Candida auris Int. J. Antimicrob. Agents 2020 56 106049 10.1016/j.ijantimicag.2020.106049 32544569 · DOI
  104. [124]Cleare L.G. Li K.L. Abuzeid W.M. Nacharaju P. Friedman J.M. Nosanchuk J.D. NO Candida auris: Nitric oxide in nanotherapeutics to combat emerging fungal pathogen Candida auris J. Fungi 2020 6 85 10.3390/jof6020085 32545506 PMC7344485 · DOI
  105. [125]Nagy F. Vitális E. Jakab Á. Borman A.M. Forgács L. Tóth Z. Majoros L. Kovács R. In vitro and in vivo effect of exogenous farnesol exposure against Candida auris Front. Microbiol. 2020 11 957 10.3389/fmicb.2020.00957 32508780 PMC7251031 · DOI
  106. [126]Shaban S. Patel M. Ahmad A. Improved efficacy of antifungal drugs in combination with monoterpene phenols against Candida auris Sci. Rep. 2020 10 1162 10.1038/s41598-020-58203-3 31980703 PMC6981193 · DOI

Cited by

Sorted by citations

Authors
Malinovská, Z., Čonková, E., & Váczi, P.
Affiliations
University of Veterinary Medicine in Košice (SK)
Corresponding author
Malinovská, Zuzana
ORCID
Venue
Journal of Fungi
Publisher
MDPI AG
Published
2023-09-22
Volume
9
Issue
10
Pages
955
ISSN
2309-608X (ISSN-L)
DOI
10.3390/jof9100955
PMC
PMC10607155
OpenAlex
W4387019916
Cited by
167
References
21
Citations by year
2026: 57 · 2025: 65 · 2024: 44 · 2023: 1
FWCI
7.92
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Fungi (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Scientific Grant Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic and the Slovak Academy of Sciences (1/0446/22)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
Keywords
biofilm formation, Candida, candidemia, invasive candidiasis, Candida albicans, Candida glabrata, Candida tropicalis, Candida parapsilosis, Candida krusei, Candida auris, antifungal resistance, disseminated fungal infection, immunocompromised patients, medical device colonization

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review